You just said it yourself, you told me 'PAR would blow OCC out of the water'. They are both primarily orthopedic companies, with massive potential in the field and other applications in their treatment technologies.
My reply was warranted by the childishness of your comment. The potential range of commercial possibilities for both companies is huge, the probabilities of either making them almost imperceivable. OCC now at least has commercial manufacturing and licensing agreements in place and is making good revenues on actual commercial sales on the least lucrative but most easily commercialised applications of its technologies that pale in comparison to PAR's OA application potential, but it's at least in the market selling TGA/FDA/EMA approved product.
You yourself know, because I've explained on there, that Orthocell could possibly be a loose competitor for PAR, as revenues will enable it to pursue it's ACI technology in knee OA. Likewise Vericel who the founders sold some of the technology to who are now going gangbusters with an FDA approved autologous chondrocyte/collagen matrix product is an already on the market competitor to PAR.
See how mature discussion on these threads can be useful information discovery for investors, rather than wasteful acrimony? I am sure many PAR investors are unaware of Vericel and may now investigate (and possibly conclude as I did, that PPS/Zilosul would be a more attractive/convenient option to many patients).
It appears from upvotes many investors were grateful for me pointing out the self fulfilling nature of a load of retail investors gathering on a retail investment forum to re-assure each other that, yes, they are absolutely right in their expectation of a share price fall due to a coming capital raise. Confirmation bias anyone?
You constructively keep slinging mud though. I will just buy a little.more PAR (and OCC if it comes lower).
PAR Price at posting:
66.0¢ Sentiment: Buy Disclosure: Held
(20min delay)